Pfizer ($PFE) has posted a fresh set of upbeat data on its top blockbuster prospect tofacitinib that will go a long way to easing the sting of its recent bapineuzumab debacle. At high doses, the oral treatment performed significantly better than a placebo in treating ulcerative colitis in a mid-stage study, offering the prospect of building a major anti-inflammatory franchise. Report
Like what you're reading?
Click here to get more news like this delivered to your inbox>>